Evidence-based Pharmacoecomic Evaluation of Venlafaxine and Escitalopram in the Treatment of Depres-sive Disorder
10.6039/j.issn.1001-0408.2017.11.05
- VernacularTitle:文拉法辛与艾司西酞普兰治疗抑郁症的循证药物经济学评价
- Author:
Biao DU
;
Yang DU
;
Xingxing XIE
;
Xiaodong FAN
;
Chunyan ZHANG
;
Wenqiang KONG
- Keywords:
Venlafaxine;
Escitalopram;
Depressive disorder;
Cost-minimization analysis;
Evidence-based pharnacoeconomic evaluation
- From:
China Pharmacy
2017;28(11):1456-1459
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically evaluate the pharnacoeconomic effect of venlafaxine and escitalopram in the treat-ment of depressive disorders. METHODS:Usingvenlafaxineescitalopramdepressiondepressive episodeantidepressantas key words,retrieved from CNKI,VIP and Wanfang database during base creation date to Dec. 2015,related literatures about venlafaxine and escitalopram in the treatment of depressive disorders were selected. The cure rate of two therapy plans for depres-sive disorders and HAMD score were analyzed statistically by cost-effectiveness analysis of pharnacoeconomics. RESULTS:There was no statistical significance in cure rate and HAMD score between 2 groups(P>0.05),so minimum-cost analysis was adopted. The costs of venlafaxine and escitalopram in the treatment of depressive disorders were 772.03 yuan and 935.77 yuan. CONCLU-SIONS:Therapeutic efficacy of venlafaxine is similar to that of escitalopram in the treatment of depressive disorders,but the for-mer scheme is more economical.
